Mackenzie Financial Corp Has $110,000 Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Mackenzie Financial Corp lowered its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 13.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 18,183 shares of the company’s stock after selling 2,936 shares during the period. Mackenzie Financial Corp’s holdings in Amneal Pharmaceuticals were worth $110,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Gladius Capital Management LP acquired a new position in Amneal Pharmaceuticals in the third quarter worth approximately $39,000. Sherbrooke Park Advisers LLC acquired a new position in Amneal Pharmaceuticals in the third quarter worth approximately $54,000. Aigen Investment Management LP acquired a new position in Amneal Pharmaceuticals in the third quarter worth approximately $118,000. Public Employees Retirement System of Ohio acquired a new position in Amneal Pharmaceuticals in the third quarter worth approximately $160,000. Finally, EMC Capital Management increased its holdings in Amneal Pharmaceuticals by 886.7% in the third quarter. EMC Capital Management now owns 40,613 shares of the company’s stock worth $171,000 after buying an additional 36,497 shares during the last quarter. Institutional investors and hedge funds own 31.82% of the company’s stock.

Analyst Ratings Changes

AMRX has been the subject of a number of recent analyst reports. StockNews.com cut Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, March 4th. Barclays upped their target price on Amneal Pharmaceuticals from $6.00 to $8.00 and gave the stock an “overweight” rating in a research report on Monday, January 29th. Piper Sandler raised their price target on Amneal Pharmaceuticals from $6.00 to $8.00 and gave the company an “overweight” rating in a research report on Thursday, March 21st. Finally, The Goldman Sachs Group lifted their price objective on Amneal Pharmaceuticals from $5.50 to $6.25 and gave the stock a “buy” rating in a research note on Monday, March 4th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Amneal Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $7.31.

Amneal Pharmaceuticals Price Performance

Shares of Amneal Pharmaceuticals stock opened at $5.94 on Tuesday. The firm has a fifty day moving average price of $5.72 and a two-hundred day moving average price of $5.22. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $1.74 and a fifty-two week high of $6.46. The company has a debt-to-equity ratio of 121.31, a current ratio of 1.63 and a quick ratio of 0.94. The company has a market cap of $1.82 billion, a PE ratio of -19.16 and a beta of 1.33.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its earnings results on Friday, March 1st. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.05 by $0.07. Amneal Pharmaceuticals had a negative net margin of 3.51% and a positive return on equity of 126.04%. The business had revenue of $616.98 million during the quarter, compared to analysts’ expectations of $630.67 million. Analysts expect that Amneal Pharmaceuticals, Inc. will post 0.5 EPS for the current year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.